Hikma Board appoints Cynthia Schwalm as Director

London, 12 March 2019 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (Hikma) announces the appointment of Cynthia Schwalm as an independent non-executive director effective 1 June 2019.

“I am very pleased that Cynthia will be joining the Hikma Board.  She brings extensive, proven experience in providing strong leadership through transformation,” said Said Darwazah, Executive Chairman. “Her extensive commercial and leadership experience in the pharmaceutical and biotech industries, as well as her experience as a healthcare practitioner will bring a fresh perspective to the board and our next stage of growth.”


Most recently, Cynthia was President and CEO of the North American divisions of the global pharmaceutical companies Ipsen and Eisai, and also held leadership positions at Amgen and Johnson & Johnson. Cynthia is a non-executive director of Caladrius Biosciences Inc., Kadman Group, and G1 Therapeutics Inc., where she chairs the Compensation Committee.


She is a member of the National Association of Corporate Directors and an angel investment group associated with the University of North Carolina, and for nearly a decade she served on the Women’s Leadership Advisory Board at Harvard University’s Kennedy School of Government.


Cynthia holds a BSN from the University of Delaware and EMBA from Wharton at the University of Pennsylvania.